SEARCH

SEARCH BY CITATION

References

  • Allison, A.C. & Engui, E.M. (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47, 85118.DOI: 10.1016/S0162-3109(00)00188-0
  • George, J.N., Woolf, S.H., Raskob, G.E., Wasser, J.S., Aledort, L.M., Ballem, P.J., Blanchette, V.S., Bussel, J.B., Cines, D.B., Kelton, J.G., Lichtin, A.E., McMillan, R., Okerbloom, J.A., Regan, D.H. & Warrier, I. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for The American Society of Hematology. Blood, 88, 340.
  • Lilleyman, J.S. (1999) Management of childhood idiopathic thrombocytopenic purpura. British Journal of Haematology, 105, 871875.
  • Simmons, W.D., Rayhill, S.C. & Sollinger, H.W. (1997) Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Safety, 17, 7592.
  • Smak Gregoor, P.J.H., Van Gelder, T. & Weimar, W. (2000) Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine. Netherlands Journal of Medicine, 57, 233246.
  • Zimmer-Molsberger, B., Knauf, W. & Thiel, E. (1997) Mycophenolate mofetil for severe autoimmune haemolytic anaemia. Lancet, 350, 10031004.